{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:49:47Z","timestamp":1789609787706,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015452","name":"Canadian Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1053\/j.ajkd.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T05:52:00Z","timestamp":1763185920000},"page":"211-229.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-6778","authenticated-orcid":false,"given":"Kevin","family":"Yau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel G.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivethika","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Castrillon-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Meraz-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.ajkd.2025.09.010_bib1","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.ekir.2022.07.167","article-title":"Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR","volume":"7","author":"Cherney","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.010_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41574-024-00951-7","article-title":"Obesity and the kidney: mechanistic links and therapeutic advances","volume":"20","author":"Yau","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.010_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.010_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1053\/j.ajkd.2025.09.010_bib5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1053\/j.ajkd.2025.09.010_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.ajkd.2025.09.010_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.010_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.09.010_bib9","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.09.010_bib11","first-page":"S144","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2025.09.010_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.kint.2021.10.033","article-title":"GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes","volume":"101","author":"Xu","year":"2022","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.09.010_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1053\/j.ajkd.2025.09.010_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1053\/j.ajkd.2025.09.010_bib16","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1210\/jc.2013-3809","article-title":"Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease","volume":"99","author":"Idorn","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.010_bib17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1365-2125.2009.03536.x","article-title":"Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide","volume":"68","author":"Jacobsen","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.010_bib18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/dom.14409","article-title":"Intensive management of obesity in people with severe chronic kidney disease: a review","volume":"23","author":"Song","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2025.09.010_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib20","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2025.09.010_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-11-25","article-title":"Validation of a case definition to define chronic dialysis using outpatient administrative data","volume":"11","author":"Clement","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.010_bib22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MLR.0b013e3181e419fd","article-title":"Using administrative datasets to study outcomes in dialysis patients: a validation study","volume":"48","author":"Quinn","year":"2010","journal-title":"Med Care"},{"issue":"19","key":"10.1053\/j.ajkd.2025.09.010_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.09.010_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40697-014-0026-5","article-title":"Canadian Organ Replacement Register (CORR): reflecting the past and embracing the future","volume":"1","author":"Moist","year":"2014","journal-title":"Can J Kidney Health Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.010_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.010_bib26","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1186\/s12913-021-06762-0","article-title":"Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study","volume":"21","author":"Lix","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1053\/j.ajkd.2025.09.010_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/2054358119887988","article-title":"Major outcomes with personalized dialysate temperature (MyTEMP): rationale and design of a pragmatic, registry-based, cluster randomized controlled trial","volume":"7","author":"Al-Jaishi","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"10.1053\/j.ajkd.2025.09.010_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/20543581211041182","article-title":"MyTEMP: statistical analysis plan of a registry-based, cluster-randomized clinical trial","volume":"8","author":"Dixon","year":"2021","journal-title":"Can J Kidney Health Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.010_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"23","key":"10.1053\/j.ajkd.2025.09.010_bib30","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.010_bib31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.010_bib32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"27","key":"10.1053\/j.ajkd.2025.09.010_bib33","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.010_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.010_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1053\/j.ajkd.2025.09.010_bib36","first-page":"1816","article-title":"Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.09.010_bib37","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1111\/dom.16424","article-title":"Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: a meta-analysis of eleven cardiovascular outcome trials","volume":"27","author":"Kang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2025.09.010_bib38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","article-title":"Peripheral arterial disease in patients with diabetes","volume":"47","author":"Marso","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101325","article-title":"Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","volume":"48","author":"Scheen","year":"2022","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies","volume":"12","author":"Caruso","year":"2022","journal-title":"Metabolites"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.010_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pcd.2021.12.007","article-title":"Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: a meta-analysis","volume":"16","author":"Du","year":"2022","journal-title":"Prim Care Diabetes"},{"issue":"13","key":"10.1053\/j.ajkd.2025.09.010_bib42","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.09.010_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.010_bib44","doi-asserted-by":"crossref","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","article-title":"Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy","volume":"289","author":"Nikolaidis","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10456","key":"10.1053\/j.ajkd.2025.09.010_bib45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.010_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.ajkd.2025.09.010_bib47","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc24-2811","article-title":"Glucagon-like peptide 1 receptor agonists and the risk of emergency department visits and hospitalization in patients with chronic kidney disease","volume":"48","author":"Yau","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2025.09.010_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2025.09.010_bib50","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2025.09.010_bib51","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.010_bib52","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial","volume":"39","author":"Idorn","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.010_bib53","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.010_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.010_bib55","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2337\/diacare.25.3.512","article-title":"Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm","volume":"25","author":"Hux","year":"2002","journal-title":"Diabetes Care"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625011497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625011497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T23:55:46Z","timestamp":1780012546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625011497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0272638625011497"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.010","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}